Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 1:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 779 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Patient Transport Clear all
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of Oxygen Delivery Through Nasal Cannula in Volunteers

NCT02886312
View directory record Official record
Conditions
Oxygen Delivery, Patient Monitoring, Patient Comfort
Interventions
Supplemental Oxygen Delivery System
Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Oct 25, 2026, 1:48 PM EDT
Recruiting Not applicable Interventional

In-patient SCC TMS

NCT05645575
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Open-label TMS
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 25, 2026, 1:48 PM EDT
Completed Not applicable Interventional Results available

Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma

NCT01005745
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Surgery, Administration of Lymphodepletion, Adoptive Cell Transfer, High Dose IL-2
Procedure · Drug · Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 25, 2026, 1:48 PM EDT
Enrolling by invitation Phase 3 Interventional

Follow-up Study of AAV-Mediated Gene Transfer (UX111; Previously Known as ABO-102) for MPS Type IIIA

NCT04360265
View directory record Official record
Conditions
Mucopolysaccharidosis IIIA, MPS IIIA, Sanfilippo Syndrome, Sanfilippo A
Interventions
No Investigational Product, Adjuvant Immunomodulatory (IM) Therapy
Other · Drug
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
Not listed
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 25, 2026, 1:48 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma

NCT03035331
View directory record Official record
Conditions
Aggressive Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Small Lymphocytic Lymphoma
Interventions
Cryosurgery, Dendritic Cell Therapy, Laboratory Biomarker Analysis, Pembrolizumab, Pneumococcal 13-valent Conjugate Vaccine, Quality-of-Life Assessment
Procedure · Biological · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 25, 2026, 1:48 PM EDT
Not yet recruiting Not applicable Interventional

PCDD Generation 1 Oral Liquid Acetaminophen Delivery Evaluation

NCT07765238
View directory record Official record
Conditions
Pain Management, Postoperative Pain
Interventions
PCDD Generation 1 system
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 25, 2026, 1:48 PM EDT
Terminated Phase 1 Interventional

Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies

NCT02070406
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cyclophosphamide, fludarabine phosphate, NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL, dendritic cell vaccine therapy, aldesleukin, fludeoxyglucose F 18, positron emission tomography, laboratory biomarker analysis
Drug · Biological · Radiation + 2 more
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
16 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2019 · Synced Oct 25, 2026, 1:48 PM EDT
Active, not recruiting Not applicable Interventional

Pivotal, Prospective, Multi-centre, Single-arm Study to Evaluate the Safety and Effectiveness of Oli for Identification of Patients, During the Intrapartum Period, Who Are at Higher Risk of Developing Abnormal Postpartum Uterine Bleeding, Including Postpartum Haemorrhage

NCT06655207
View directory record Official record
Conditions
Post Partum Haemorrhage, Maternal Care Patterns, High Risk Pregnancy
Interventions
Oli is a non-invasive, wearable device, designed to provide clinicians with an early indication if the participant is at a higher risk of developing abnormal postpartum uterine bleeding
Device
Lead sponsor
Baymatob Operations Pty Ltd
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Denver, Colorado • Baton Rouge, Louisiana • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 25, 2026, 1:48 PM EDT
Completed Not applicable Interventional

Coaches Activating Reaching and Engaging Patients

NCT03856463
View directory record Official record
Conditions
Cancer, End-of-Life
Interventions
Lay Navigator Intervention, Usual Care
Behavioral · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Oct 25, 2026, 1:48 PM EDT
Completed Phase 2 Interventional Results available

Continuous Infusion Terlipressin for Patients With Cirrhosis and Refractory Ascites

NCT03107091
View directory record Official record
Conditions
Cirrhosis, Ascites Hepatic
Interventions
Terlipressin acetate continuous infusion
Drug
Lead sponsor
BioVie Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Oct 25, 2026, 1:48 PM EDT
Completed Not applicable Interventional

Creation of an Infrastructure to Support Delivery of mHealth Interventions for Cancer Patients

NCT06909357
View directory record Official record
Conditions
Smoking Cessation
Interventions
Quitline Treatment (QT), App-based Treatment (mHealth)
Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Coral Gables, Florida • Gainesville, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 25, 2026, 1:48 PM EDT
Recruiting Phase 3 Interventional

Cleavage-stage Versus Blastocyst-stage Embryo Transfer in IVF Patients With Few Embryos

NCT06746129
View directory record Official record
Conditions
Infertility (IVF Patients)
Interventions
embryo transfer
Procedure
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
1,126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 25, 2026, 1:48 PM EDT
Completed Phase 1 Interventional

Photodynamic Therapy System for Patients With Refractory/Unresponsive Solid Tumors

NCT00028405
View directory record Official record
Conditions
Liver Metastasis, Pelvic Cancer, Head and Neck Cancer, Sarcoma, Rectal Cancer, Breast Cancer, Colorectal Cancer, Mouth Cancer
Interventions
LS 11(Taporfin Sodium), Lumaflex Light Delivery Catheter
Drug · Device
Lead sponsor
Light Sciences LLC
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
6
States / cities
Tucson, Arizona • Detroit, Michigan • Greenville, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 25, 2026, 1:48 PM EDT
Completed Phase 1 Interventional

CArdiosphere-Derived aUtologous Stem CElls to Reverse ventricUlar dySfunction

NCT00893360
View directory record Official record
Conditions
Recent Myocardial Infarction, Ventricular Dysfunction
Interventions
Autologous stem cell infusion
Biological
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Los Angeles, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 12, 2014 · Synced Oct 25, 2026, 1:48 PM EDT
Completed Not applicable Interventional Results available

A Study of the Feasibility of Prehospital Remote Ischemic Conditioning

NCT03400579
View directory record Official record
Conditions
Chest Pain
Interventions
autoRIC® device
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Oct 25, 2026, 1:48 PM EDT
Completed Phase 1 Interventional

PK Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Patients Undergoing Vitrectomy

NCT02644694
View directory record Official record
Conditions
Vitrectomy
Interventions
Dexamethasone Phosphate Ophthalmic Solution
Drug
Lead sponsor
Eyegate Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Oct 25, 2026, 1:48 PM EDT
Recruiting Not applicable Interventional

Novel Cavity Marking Technique in Breast Cancer Patients Undergoing Breast Conservation Surgery With Oncoplastic Reconstruction for the Delivery of Adjuvant Radiotherapy and Accuracy of Recommended Re-excisions

NCT06903468
View directory record Official record
Conditions
Ductal Carcinoma in Situ, Breast Cancer
Interventions
Novel cavity marking technique
Procedure
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 25, 2026, 1:48 PM EDT
Withdrawn Phase 2 Interventional

Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer

NCT03419559
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
LN-145, Durvalumab
Biological · Drug
Lead sponsor
Iovance Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
8
States / cities
La Jolla, California • Los Angeles, California • Louisville, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 25, 2026, 1:48 PM EDT
Completed Not applicable Interventional Results available

Regional Data Exchange to Improve Care for Veterans After Non-VA Hospitalization

NCT02689076
View directory record Official record
Conditions
Patient Readmission, Adverse Drug Event, Cost
Interventions
HIE Notification, Care transitions intervention
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
65 Years and older
Enrollment
796 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Indianapolis, Indiana • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 25, 2026, 1:48 PM EDT
Active, not recruiting Not applicable Interventional

A Multimedia Presentation to Augment the Informed Consent Process for Anesthesia for Patients Undergoing Scheduled Caesarian Delivery

NCT06945250
View directory record Official record
Conditions
Pregnancy, Caesarean Section
Interventions
Experimental Audio Visual
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 25, 2026, 1:48 PM EDT
Completed Phase 2 Interventional Results available

CerviPrep for Applying Topical Gemcitabine to the Cervix in Treating Patients With Primary Endometrial, Cervical, or Ovarian Epithelial Cancer

NCT00610740
View directory record Official record
Conditions
Cervical Cancer, Endometrial Cancer, Ovarian Cancer
Interventions
topical gemcitabine hydrochloride, therapeutic conventional surgery
Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 25, 2026, 1:48 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

mPATH-Cloud for Colorectal Cancer Screening

NCT06441487
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Mobile Health Decision Support, Usual care
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
45 Years to 73 Years
Enrollment
1,062 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 25, 2026, 1:48 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of LNP.UCD.ABE in Patients With Urea Cycle Disorders

NCT07667387
View directory record Official record
Conditions
Urea Cycle Disorders, Carbamoyl-Phosphate Synthase I Deficiency
Interventions
LNP.UCD.ABE
Biological
Lead sponsor
Rebecca Ahrens-Nicklas
Other
Eligibility
24 Hours to 5 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 25, 2026, 1:48 PM EDT
Completed Phase 2 Interventional Results available

Effect of Ileal Bile Acid Transporter Inhibitor in Functional Constipation

NCT01038687
View directory record Official record
Conditions
Functional Constipation
Interventions
A3309, placebo
Drug
Lead sponsor
Michael Camilleri, MD
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 4, 2020 · Synced Oct 25, 2026, 1:48 PM EDT